Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Receivables (2020 - 2025)

Oncology Institute's Receivables history spans 6 years, with the latest figure at $59.3 million for Q4 2025.

  • For Q4 2025, Receivables rose 21.85% year-over-year to $59.3 million; the TTM value through Dec 2025 reached $59.3 million, up 21.85%, while the annual FY2025 figure was $59.3 million, 21.85% up from the prior year.
  • Receivables reached $59.3 million in Q4 2025 per TOI's latest filing, down from $60.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $60.0 million in Q3 2025 to a low of $21.2 million in Q4 2021.
  • Average Receivables over 5 years is $45.8 million, with a median of $48.7 million recorded in 2024.
  • Peak YoY movement for Receivables: soared 90.33% in 2022, then decreased 16.0% in 2025.
  • A 5-year view of Receivables shows it stood at $21.2 million in 2021, then skyrocketed by 90.33% to $40.4 million in 2022, then rose by 6.13% to $42.9 million in 2023, then grew by 13.45% to $48.7 million in 2024, then rose by 21.85% to $59.3 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Receivables are $59.3 million (Q4 2025), $60.0 million (Q3 2025), and $55.9 million (Q2 2025).